EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective�…

JF Gainor, AT Shaw, LV Sequist, X Fu, CG Azzoli…�- Clinical cancer�…, 2016 - AACR
Purpose: PD-1 inhibitors are established agents in the management of non–small cell lung
cancer (NSCLC); however, only a subset of patients derives clinical benefit. To determine�…
Save Cite Cited by 1127 Related articles

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective�…

JF Gainor, AT Shaw, LV Sequist, X Fu…�- …�Cancer Research: an�…, 2016 - europepmc.org
Purpose PD-1 inhibitors are established agents in the management of non-small cell lung
cancer (NSCLC); however, only a subset of patients derives clinical benefit. To determine�…
Cite
[HTML] nih.gov

[HTML][HTML] EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer (NSCLC): A�…

JF Gainor, AT Shaw, LV Sequist, X Fu…�- …�cancer research: an�…, 2016 - ncbi.nlm.nih.gov
Purpose PD-1 inhibitors are established agents in the management of non-small cell lung
cancer (NSCLC); however, only a subset of patients derives clinical benefit. To determine�…
Cite

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective�…

JF Gainor, AT Shaw, LV Sequist…�- …�: an official journal�…, 2016 - pubmed.ncbi.nlm.nih.gov
Purpose PD-1 inhibitors are established agents in the management of non-small cell lung
cancer (NSCLC); however, only a subset of patients derives clinical benefit. To determine�…
Cite

EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis

JF Gainor, AT Shaw, LV Sequist, X Fu…�- Clinical Cancer�…, 2016 - portalrecerca.uab.cat
Purpose: PD-1 inhibitors are established agents in the management of non-small cell lung
cancer (NSCLC); however, only a subset of patients derives clinical benefit. To determine�…
Cite

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective�…

JF Gainor, AT Shaw, LV Sequist, X Fu…�- Clinical Cancer�…, 2016 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Purpose: PD-1 inhibitors are established
agents in the management of non–small cell lung cancer (NSCLC); however, only a subset�…
Cite

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective�…

JF Gainor, AT Shaw, LV Sequist, X Fu…�- …�Cancer Research: an�…, 2016 - europepmc.org
Purpose PD-1 inhibitors are established agents in the management of non-small cell lung
cancer (NSCLC); however, only a subset of patients derives clinical benefit. To determine�…
Cite